Publications by authors named "Dimitri Pogodin-Hannolainen"
Article Synopsis
- In 2020, the European Association of Urology introduced a new classification system named EAUiaiC to better grade intraoperative adverse events during urology surgeries, specifically aimed at kidney tumor procedures.
- A study was conducted in Finland reviewing 749 radical and 531 partial nephrectomies to validate the EAUiaiC, finding that 13.8% of radical nephrectomy patients and 6.4% of partial nephrectomy patients experienced intraoperative adverse events, primarily due to bleeding.
- The results showed significant links between adverse events and factors like tumor size and surgical approach, highlighting that the EAUiaiC classification is effective in identifying risks, with bleeding being a critical concern in
Background: There is huge variation in Clavien-Dindo (CD) complication rates in urology. We sought to optimize the use of the CD system in kidney tumor surgery.
Methods: We retrospectively analyzed 1,286 patients undergoing kidney tumor operations in 12 Finnish hospitals during 2016-2017.
Background: Neoadjuvant chemotherapy (NAC) is underutilized in the treatment of bladder cancer (BC).
Objective: To investigate the effect of NAC on the risk of surgical complications for radical cystectomy (RC) in a population-based setting.
Design, Setting, And Participants: All radical cystectomies performed in Finland during 2005-2014 were included in the study.
Purpose: Screening for prostate cancer remains controversial, although ERSPC (European Randomized Study of Screening for Prostate Cancer) showed a 21% relative reduction in prostate cancer mortality. The Finnish Randomized Study of Screening for Prostate Cancer, which is the largest component of ERSPC, demonstrated a statistically nonsignificant 16% mortality benefit in a separate analysis. The purpose of this study was to estimate the degree of contamination in the control arm of the Finnish trial.
View Article and Find Full Text PDFObjective: To evaluate the attitudes and practices related to prostate-specific antigen (PSA) screening for prostate cancer (PC) among Finnish physicians in 1999 and 2007.
Materials And Methods: The first questionnaire survey was conducted in 1999 with a mailing to 102 urologists, 679 community physicians and 684 occupational health physicians identified from the membership files of three medical associations. The area of residence was divided into the study area of the Finnish PC screening trial and the rest of Finland.